ID: ALA3134467

Max Phase: Preclinical

Molecular Formula: C23H26ClN3O5S

Molecular Weight: 492.00

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOC(=O)C1CCCN(c2ccc(N3C[C@H](CNC(=O)c4ccc(Cl)s4)OC3=O)cc2)C1

Standard InChI:  InChI=1S/C23H26ClN3O5S/c1-2-31-22(29)15-4-3-11-26(13-15)16-5-7-17(8-6-16)27-14-18(32-23(27)30)12-25-21(28)19-9-10-20(24)33-19/h5-10,15,18H,2-4,11-14H2,1H3,(H,25,28)/t15?,18-/m0/s1

Standard InChI Key:  ABXJLQSCNDLRCW-PKHIMPSTSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 492.00

Molecular Weight (Monoisotopic): 491.1282

AlogP: 3.94

#Rotatable Bonds: 7

Polar Surface Area: 88.18

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.60

CX Basic pKa: 3.94

CX LogP: 3.98

CX LogD: 3.98

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.59

Np Likeness Score: -1.69

References

1. Trstenjak U, Ilas J, Kikelj D.  (2014)  Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety,  5  (2): [10.1039/C3MD00250K]

Source

Source(1):

• Scientific Literature